CY1111494T1 - ΑΝΑΣΥΝΔΥΑΣΜΕΝΟΣ ΑΔΕΝΟΪΟΣ ΤΟΥ Αd26 ΟΡΟΤΥΠΟΥ - Google Patents

ΑΝΑΣΥΝΔΥΑΣΜΕΝΟΣ ΑΔΕΝΟΪΟΣ ΤΟΥ Αd26 ΟΡΟΤΥΠΟΥ

Info

Publication number
CY1111494T1
CY1111494T1 CY20111100030T CY111100030T CY1111494T1 CY 1111494 T1 CY1111494 T1 CY 1111494T1 CY 20111100030 T CY20111100030 T CY 20111100030T CY 111100030 T CY111100030 T CY 111100030T CY 1111494 T1 CY1111494 T1 CY 1111494T1
Authority
CY
Cyprus
Prior art keywords
serotypes
natural
proteins
tropics
capsid
Prior art date
Application number
CY20111100030T
Other languages
English (en)
Inventor
Ronald Vogels
Menzo Jans Emko Havenga
Abraham Bout
Original Assignee
Crucell Holland B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111494(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland B.V. filed Critical Crucell Holland B.V.
Publication of CY1111494T1 publication Critical patent/CY1111494T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345Special targeting system for viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Οι ορότυποι διαφέρουν στο φυσικό τροπισμό αυτών. Οι ορότυποι 2, 4, 5 και 7 αδενοϊού έχουν όλοι μία φυσική θυγατρική σχέση προς τους επιθηλίους του πνεύμονα και άλλους αναπνευστικούς ιστούς. Αντιθέτως, οι ορότυποι 40 και 41 έχουν φυσική θυγατρική σχέση προς τη γαστροεντερική οδό. Οι ορότυποι που περιγράφονται παραπάνω, διαφέρουν σε τουλάχιστον πρωτεΐνες καψιδίου (με βάση πεντόνιο, εξόνιο), πρωτεΐνες υπεύθυνες για σύνδεση κυττάρου (πρωτεΐνη ίνας) και πρωτεΐνες που ενέχονται σε αντιγραφή αδενοϊού. Αυτή η διαφορά στο τροπισμό και πρωτεΐνη καψιδίου μεταξύ οροτύπων έχει οδηγήσει σε πολλές ερευνητικές προσπάθειες που στοχεύουν την επανακατεύθυνση του τροπισμού αδενοϊού με τροποποίηση των πρωτεϊνών καψιδίου.
CY20111100030T 1999-05-17 2011-01-10 ΑΝΑΣΥΝΔΥΑΣΜΕΝΟΣ ΑΔΕΝΟΪΟΣ ΤΟΥ Αd26 ΟΡΟΤΥΠΟΥ CY1111494T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201545 1999-05-17
EP07106044A EP1816204B1 (en) 1999-05-17 2000-05-16 Recombinant Adenovirus of the Ad26 serotype

Publications (1)

Publication Number Publication Date
CY1111494T1 true CY1111494T1 (el) 2015-08-05

Family

ID=8240209

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20071100996T CY1106762T1 (el) 1999-05-17 2007-07-25 Ανασυνδυασμενος ανθρωπινος αδενοϊος οροτυπου 35
CY20111100030T CY1111494T1 (el) 1999-05-17 2011-01-10 ΑΝΑΣΥΝΔΥΑΣΜΕΝΟΣ ΑΔΕΝΟΪΟΣ ΤΟΥ Αd26 ΟΡΟΤΥΠΟΥ
CY20111101074T CY1112008T1 (el) 1999-05-17 2011-11-07 Ανασυνδυασμενος αδενοϊος οροτυπου ad11
CY20111101075T CY1112189T1 (el) 1999-05-17 2011-11-07 Ανασυνδυασμενος αδενοϊος βασιζομενος στον οροτυπο 48 (ad48)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20071100996T CY1106762T1 (el) 1999-05-17 2007-07-25 Ανασυνδυασμενος ανθρωπινος αδενοϊος οροτυπου 35

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20111101074T CY1112008T1 (el) 1999-05-17 2011-11-07 Ανασυνδυασμενος αδενοϊος οροτυπου ad11
CY20111101075T CY1112189T1 (el) 1999-05-17 2011-11-07 Ανασυνδυασμενος αδενοϊος βασιζομενος στον οροτυπο 48 (ad48)

Country Status (14)

Country Link
EP (6) EP1816205B1 (el)
JP (2) JP4843145B2 (el)
KR (1) KR100741247B1 (el)
AT (6) ATE445018T1 (el)
AU (1) AU777041B2 (el)
CA (1) CA2372655C (el)
CY (4) CY1106762T1 (el)
DE (4) DE60045138D1 (el)
DK (6) DK1816205T3 (el)
ES (5) ES2289426T3 (el)
IL (3) IL146479A0 (el)
NZ (1) NZ515582A (el)
PT (5) PT1054064E (el)
WO (1) WO2000070071A1 (el)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (en) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gene delivery vectors provided with a tissue tropism for T-lymphocytes
EP1285079A2 (en) 2000-05-31 2003-02-26 University of Saskatchewan Modified bovine adenovirus having altered tropism
CA2421864A1 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
WO2002029073A2 (en) * 2000-10-06 2002-04-11 Crucell Holland B.V. Gene delivery vectors for stem cells
EP1195440A1 (en) * 2000-10-06 2002-04-10 Introgene B.V. Gene delivery vectors for stem cells
EP1348030B1 (en) 2001-01-04 2009-11-25 Wadell, Göran Viral vector for gene therapy
EP1377672A2 (en) 2001-02-23 2004-01-07 Novartis AG Vector constructs
CA2474763A1 (en) * 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
PL208588B1 (pl) 2002-04-25 2011-05-31 Crucell Holland Bv Rekombinowane adenowirusy, wyizolowane kwasy nukleinowe, komórki pakujące oraz sposoby zwiększania stabilności i/lub pojemności upakowania rekombinowanego adenowirusa
JP4495587B2 (ja) * 2002-04-25 2010-07-07 クルセル ホランド ベー ヴェー 組換えアデノウイルスベクターおよびその使用
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
SG156535A1 (en) 2002-12-17 2009-11-26 Crucell Holland Bv Recombinant viral-based malaria vaccines
US20050036989A1 (en) * 2003-07-18 2005-02-17 Onyx Pharmaceuticals, Inc. Subgroup B adenoviral vectors for treating disease
NZ548495A (en) 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
JP2007532656A (ja) * 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
ATE491799T1 (de) 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
BRPI0518933A2 (pt) 2004-11-16 2008-12-16 Crucell Holland B V E Aeras Gl adenovÍrus recombinante defeituoso de replicaÇço, vetor de polinucleotÍdeo recombinante, vacina multivalente da tuberculose, e, uso do antÍgeno tb10.4 de mycobacterium
DK1869171T4 (en) 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
ATE463559T1 (de) 2005-07-22 2010-04-15 Crucell Holland Bv Zelllinie zur produktion von coronaviren
US20100143302A1 (en) * 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
JP5770633B2 (ja) 2008-11-03 2015-08-26 クルセル ホランド ベー ヴェー アデノウイルスベクターの産生方法
WO2011015656A2 (en) 2009-08-07 2011-02-10 Transgene Sa Composition for treating hbv infection
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
US20120315696A1 (en) * 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
CA2809463C (en) 2010-09-27 2021-05-25 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
CN104334188B (zh) 2012-03-22 2016-08-24 克鲁塞尔荷兰公司 抗rsv疫苗
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
US9476061B2 (en) 2012-05-24 2016-10-25 Janssen Vaccines & Prevention B.V. Adenoviral vectors for transduction of vascular tissue
BR112015000530A2 (pt) 2012-07-10 2018-08-28 Transgene Sa vacina de antígeno micobacteriano.
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
CA3200425A1 (en) 2012-11-16 2014-05-22 Peter ABBINK Recombinant adenoviruses and use thereof
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
AP2015008893A0 (en) 2013-06-17 2015-12-31 Crucell Holland Bv Stabilized soluble pre-fusion rsv f polypeptides
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
SG11201605595YA (en) 2014-01-09 2016-08-30 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
SI3188753T1 (sl) 2014-09-03 2020-07-31 Bavarian Nordic A/S Metode in sestave za induciranje zaščitne imunosti proti okužbi s filovirusom
CA2960096A1 (en) 2014-09-03 2016-03-10 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
PT3197489T (pt) 2014-09-26 2021-04-30 Beth Israel Deaconess Medical Ct Inc Métodos e composições para induzir a imunidade protetora contra a infeção pelo vírus da imunodeficiência humana
LT3215187T (lt) 2014-11-04 2018-12-27 Janssen Vaccines & Prevention B.V. Terapinės hpv16 vakcinos
AU2016249798B2 (en) 2015-04-14 2022-05-26 Janssen Vaccines And Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CN108396015B (zh) 2015-04-30 2022-02-18 皮斯奥克斯治疗公司 编码b7蛋白质的溶瘤腺病毒
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化された可溶性融合前rsv fポリペプチド
SG10202001501QA (en) 2015-08-20 2020-04-29 Janssen Vaccines & Prevention Bv Therapeutic hpv18 vaccines
JP6510149B2 (ja) 2015-12-15 2019-05-08 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法
KR20180107105A (ko) 2015-12-17 2018-10-01 싸이오서스 테라퓨틱스 엘티디. 항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
KR102471633B1 (ko) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
PE20190433A1 (es) 2016-04-05 2019-03-21 Janssen Vaccines And Prevention B V Vacuna contra vrs
ES2858315T3 (es) 2016-04-05 2021-09-30 Janssen Vaccines & Prevention Bv Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用hpvワクチン組み合わせ
IL264119B2 (en) 2016-05-30 2023-04-01 Janssen Vaccines Prevention B V f proteins of rsv are stabilized before fusion
BR112018075785A2 (pt) 2016-06-16 2019-04-02 Janssen Vaccines & Prevention B.V. formulação de vacina para o hiv
MX2018015540A (es) 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Hpvワクチン
EP3484505A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
EP3484507A1 (en) 2016-07-15 2019-05-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN110268061A (zh) 2017-02-09 2019-09-20 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
EP3606553A1 (en) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. Rsv感染に対する防御免疫を誘導するための方法及び組成物
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2018229711A1 (en) 2017-06-15 2018-12-20 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding hiv antigens, and methods of use thereof
AU2018333566A1 (en) 2017-09-15 2020-02-27 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
WO2019099970A1 (en) 2017-11-20 2019-05-23 Janssen Pharmaceuticals Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
EP3723771A4 (en) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. RECOMBINANT ADENOVIRUS AND THEIR USES
MA51312A (fr) 2017-12-19 2020-10-28 Bavarian Nordic As Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
BR112021000274A2 (pt) 2018-07-20 2021-04-06 Janssen Vaccines & Prevention B.V. Vetor adenoviral recombinante expressando antígeno de zika com produtividade melhorada
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
US20220193219A1 (en) 2019-05-15 2022-06-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
CN111337042B (zh) * 2020-03-13 2021-11-02 湖北大学 一种车辆路径规划方法及系统
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
KR20230050328A (ko) 2020-07-08 2023-04-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv에 대한 rna 레플리콘 백신
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
EP4267605A2 (en) 2020-12-23 2023-11-01 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
WO2000052186A1 (en) * 1999-03-04 2000-09-08 Introgene B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
CA2726914A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections

Also Published As

Publication number Publication date
DK1818408T3 (da) 2011-10-17
ATE485382T1 (de) 2010-11-15
EP1816204B1 (en) 2010-10-20
EP1054064B1 (en) 2004-10-06
PT1816205E (pt) 2011-11-15
DE60014489D1 (de) 2004-11-11
ES2289426T3 (es) 2008-02-01
EP1054064A1 (en) 2000-11-22
CY1112008T1 (el) 2015-11-04
DE60043126D1 (de) 2009-11-19
JP2011224014A (ja) 2011-11-10
PT1818408E (pt) 2011-11-15
DE60014489T2 (de) 2005-11-24
ATE445018T1 (de) 2009-10-15
DE60035229D1 (de) 2007-07-26
EP1550722A1 (en) 2005-07-06
DK1816205T3 (da) 2011-11-21
KR100741247B1 (ko) 2007-07-19
ES2372824T3 (es) 2012-01-26
ES2231103T3 (es) 2005-05-16
NZ515582A (en) 2003-11-28
EP1816205B1 (en) 2011-08-10
CY1106762T1 (el) 2012-05-23
EP1818408B1 (en) 2011-08-10
AU777041B2 (en) 2004-09-30
CA2372655A1 (en) 2000-11-23
IL214413A0 (en) 2011-09-27
ATE519854T1 (de) 2011-08-15
JP2002543846A (ja) 2002-12-24
ATE278792T1 (de) 2004-10-15
AU4954700A (en) 2000-12-05
IL146479A0 (en) 2002-07-25
EP1818408A1 (en) 2007-08-15
PT1054064E (pt) 2005-02-28
JP4843145B2 (ja) 2011-12-21
ATE519855T1 (de) 2011-08-15
DE60045138D1 (de) 2010-12-02
IL146479A (en) 2011-12-29
ES2354578T3 (es) 2011-03-16
PT1550722E (pt) 2007-09-25
PT1816204E (pt) 2011-01-24
EP1816204A1 (en) 2007-08-08
CA2372655C (en) 2011-11-15
ES2231103T5 (es) 2010-04-15
DK1681353T3 (da) 2010-01-04
EP1054064B2 (en) 2009-12-16
DE60035229T2 (de) 2008-02-21
DK1054064T3 (da) 2005-01-10
EP1681353B1 (en) 2009-10-07
CY1112189T1 (el) 2015-12-09
EP1550722B1 (en) 2007-06-13
JP5335037B2 (ja) 2013-11-06
KR20020028879A (ko) 2002-04-17
EP1816205A1 (en) 2007-08-08
DK1054064T4 (da) 2010-05-03
DK1816204T3 (da) 2011-01-24
IL214413A (en) 2014-04-30
DK1550722T3 (da) 2007-10-08
DE60014489T3 (de) 2010-08-12
WO2000070071A1 (en) 2000-11-23
ES2372823T3 (es) 2012-01-26
ATE364707T1 (de) 2007-07-15
EP1681353A1 (en) 2006-07-19

Similar Documents

Publication Publication Date Title
CY1111494T1 (el) ΑΝΑΣΥΝΔΥΑΣΜΕΝΟΣ ΑΔΕΝΟΪΟΣ ΤΟΥ Αd26 ΟΡΟΤΥΠΟΥ
LT2003107A (en) Pulmonary adminstration of chemically modified insulin
SE9403245D0 (sv) Improvements relating to bilayer lipid membranes
CY1110462T1 (el) Θεραπεια της ηπατικης ινωσης με αντισωματα εναντιον της ενσωματινης (ιντεγκρινης) αλφα v βητα 6
EE05538B1 (et) Interleukiin-18 seostuvad valgud, nende valmistamine ja kasutamine
CY1117307T1 (el) Μεταφορα γονιδιου εντος επιθηλιακου βλαστοκυτταρου αεροδου με χρηση φακοϊικου φορεα ψευδοτυποποιημενου με πρωτεϊνη αιχμης rna ιου
NO20020367L (no) Konjugater og fremgangsmåter for fremstilling derav, og deres anvendelse for transportering av molekyler via biologiskemembraner
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
MXPA05004074A (es) Nuevos adenovirus, acidos nucleicos que los codifican y su uso.
NO983375D0 (no) Retroviral vektor og anvendelse derav i genterapi
BRPI0100837B8 (pt) sequência de dna que codifica a proteína externa de membrana antigênica e específica de salmonella typhi
WO2007081938A3 (en) Mannheimia haemolytica chimeric outer membrane protein plpe and leukotoxin epitopes as a vaccine or vaccine component against shipping fever
ATE382098T1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
ATE430758T1 (de) Lipid-aminoglykosid konjugate zur transfektion
Chin Rescuing Glycine
Kiyomitsu et al. Elastase Inhibitor Elafin Is a New Type of Proteinase Inhibitor Which Has a Transglutaminase-Mediated Anchoring Sequence Termed" Cementoin".
Hamilton No red faces, they hope.
Vouton ANNA MITRAKI
Matthews Living your best life: Ten strategies for getting from where you are to where you're meant to be.
SE0102998L (sv) Anordning och sätt för att forma en matta
DE502004008072D1 (de) Pflugkörper